ARTELO BIOSCIENCES INC (ARTL) Stock News

USA - NASDAQ:ARTL - US04301G6070 - Common Stock

3.38 USD

-0.03 (-0.88%)

Last: 10/24/2025, 8:09:28 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ARTL Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Artelo Biosciences

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

24 days ago - By: Artelo Biosciences

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

25 days ago - By: Benzinga - Mentions: NBY APDN CANF CLGN ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

25 days ago - By: Benzinga - Mentions: SPRC BIAF MSS EPOW ...

Why Wolfspeed Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket

26 days ago - By: Artelo Biosciences

Artelo Biosciences Announces Proposed Underwritten Public Offering

a month ago - By: Artelo Biosciences

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

2 months ago - By: Artelo Biosciences

Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms

2 months ago - By: Artelo Biosciences

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

2 months ago - By: Artelo Biosciences

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

2 months ago - By: Artelo Biosciences

Artelo Biosciences Announces Proposed Underwritten Public Offering

2 months ago - By: Artelo Biosciences

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

2 months ago - By: Artelo Biosciences

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

2 months ago - By: Artelo Biosciences

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

2 months ago - By: Artelo Biosciences

Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results

3 months ago - By: Artelo Biosciences

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

3 months ago - By: Artelo Biosciences

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

3 months ago - By: Artelo Biosciences

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

4 months ago - By: Artelo Biosciences

Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium